natgillin/translations-raw huggingface dataset:
Men der kan opstå svimmelhed og kvalme, som er almindelige bivirkninger.
dizziness and nausea are common side effects which may occur.
Dyrereproduktionsstudier af formoterol har vist en lidt reduceret frugtbarhed hos hanrotter ved høj systemisk eksponering og implantationstab, samt nedsat tidlig postnatal overlevelse og fødselsvægt ved væsentligt højere systemiske eksponeringer end dem, der blev opnået under klinisk brug.
Animal reproduction studies with formoterol have shown a slightly reduced fertility in male rats at high systemic exposure and implantation losses, as well as decreased early postnatal survival and birth weight at considerably higher systemic exposures than those reached during clinical use.
Hos patienter med svær KOL kan hypokaliæmi potenseres af hypoksi og samtidig behandling (se pkt.
In patients with severe COPD, hypokalaemia may be potentiated by hypoxia and concomitant treatment (see section 4.5).
Inhalation af høje doser β2-adrenerge agonister kan medføre forhøjet plasmaglukose.
Inhalation of high doses of β2-adrenergic agonists may produce increases in plasma glucose.
Omryst inhalatoren omhyggeligt før hvert klargøringspust.
Shake the inhaler well before each priming puff.
• Pilen peger på 100, når du har taget yderligere 10 doser.
• The pointer points to 100 after you take 10 more puffs.
Der er ingen relevant data om brugen af Bevespi Aerosphere til patienter med svær leverinsufficiens, og lægemidlet bør anvendes med forsigtighed til disse patienter (se pkt.
There are no relevant data on the use of Bevespi Aerosphere in patients with severe hepatic impairment and the medicinal product should be used with caution in these patients (see sections 4.4 and 5.2).
En populationsfarmakokinetisk analyse af glycopyrronium blev udført baseret på data indsamlet fra i alt 311 forsøgspersoner med KOL.
A population pharmacokinetic analysis of glycopyrronium was performed based on data collected in a total of 311 subjects with COPD.
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal du spørge din læge eller apotekspersonalet til råds, før du bruger Bevespi Aerosphere.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking Bevespi Aerosphere.
Som en konsekvens af differencetætheden af muskarinreceptorer og β2-adrenoceptorer i de centrale og perifere luftveje i lungen, er muskarine antagonister mere effektive til afslapning af de centrale luftveje, og β2-adrenerge agonister er mere effektive til afslapning af de perifere luftveje.
As a consequence of the differential density of muscarinic receptors and β2-adrenoceptors in the central and peripheral airways of the lung, muscarinic antagonists are more effective in relaxing central airways, and β2-adrenergic agonists are more effective in relaxing peripheral airways; relaxation of both central and peripheral airways with combination treatment may contribute to its beneficial effects on lung function.
Trin 2: Tag hætten af mundstykket
Step 2: Take the cap off the mouthpiece.
Trin 3: Hold inhalatoren med mundstykket pegende mod dig og ånd ud gennem munden, så meget som du kan (se figur 8).
Step 3: Hold the inhaler with the mouthpiece pointing towards you and breathe out as fully as you comfortably can through your mouth (See Figure 8).
I reproduktionsstudier hos dyr har henholdsvis formoterol og glycopyrronium forårsaget uønskede virkninger ved meget høje doser/systemiske eksponeringsniveauer (se pkt.
In animal studies formoterol and glycopyrronium, individually, have caused adverse effects in reproduction studies at very high doses/systemic exposure levels (see section 5.3).
Efter en inhalation af Bevespi Aerosphere hos forsøgspersoner med KOL, forekom glycopyrronium Cmax efter cirka 5 minutter og formoterol Cmax forekom inden for 20-60 minutter.
Following inhaled administration of Bevespi Aerosphere in subjects with COPD, glycopyrronium Cmax occurred at approximately 5 minutes, and formoterol Cmax occurred within 20 to 60 minutes.
• Dosisindikatoren i dosisindikatorvinduet vil bevæge sig for hver 10. dosis.
• The dose indicator display window will move after every 10 puffs.
Brug ikke inhalatoren, hvis tørremidlet er lækket ud af pakken.
Do not use the inhaler if the drying agent has leaked out of its packet.
EU/1/18/1339/002 360 pust (3 inhalatorer med 120 pust hver)
EU/1/18/1339/002 360 actuations (3 packs of 120 actuations)
Må ikke udsættes for temperaturer over 50 C.
Do not expose to temperatures higher than 50°C.
Der er påvist kompatibilitet med Aerochamber Plus Flow-Vu spacerenhed (se pkt.
Compatibility with the Aerochamber Plus Flow-Vu spacer device has been demonstrated (see section 5.2).
• Brug ikke inhalatoren, hvis tørremidlet, som ligger inden i foliet, har lækket.
• Not use the inhaler if the drying agent, which is inside the foil pouch, has leaked out of its packet.
Baseret på tilgængelige data er dosisjustering af Bevespi Aerosphere til ældre patienter ikke nødvendig.
Based on available data, no adjustment of the dosage of Bevespi Aerosphere in geriatric patients is necessary.
Det frarådes at bruge Bevespi Aerosphere sammen med disse lægemidler:
It is not recommended to use Bevespi Aerosphere together with these medicines;
Bevespi Aerosphere indeholder to bronkodilatorer: glycopyrronium, en langtidsvirkende muskarinreceptorantagonist (også kaldet et antikolinergikum) og formoterol, en langtidsvirkende β2-adrenerg agonist med hurtig virkning.
Bevespi Aerosphere contains two bronchodilators: glycopyrronium a long-acting muscarinic antagonist (also referred to as an anticholinergic) and formoterol a long-acting β2-adrenergic agonist with a rapid onset of action.
Glycopyrronium udskilles primært fra det systemiske kredsløb ved nyrerne, og leverinsufficiens forventes derfor ikke at føre til skadelig systemisk eksponering.
Glycopyrronium is primarily cleared from the systemic circulation by renal excretion and hepatic impairment would therefore not be expected to lead to unsafe systemic exposure.
• du har problemer med skjoldbruskkirtlen (kaldet tyrotoksikose)
• you have thyroid gland problems (called ‘thyrotoxicosis')
• Bevespi Aerosphere leveres med en dosisindikator øverst på trykbeholderen (se figur 1).
• Bevespi Aerosphere comes with a dose indicator on the top of the pressurised container (See Figure 1).
Virkning på lungefunktion
Effects on lung function
Rastløshed Søvnløshed
Agitation Restlessness Insomnia
Paradoks bronkospasme blev ikke set i kliniske studier af Bevespi Aerosphere i anbefalede doser.
In clinical studies, paradoxical bronchospasm was not observed with Bevespi Aerosphere at its recommended dose.
Trin 6: Lad plasthylsteret lufttørre natten over (se figur 17).
Step 6: Let the actuator air-dry overnight (See Figure 17).
Kontakt lægen eller apotekspersonalet, før du bruger Bevespi Aerosphere, hvis:
Talk to your doctor or pharmacist before using Bevespi Aerosphere if:
Dette omfatter: o kortikosteroider, som du tager gennem munden (såsom prednisolon) o vanddrivende medicin (såsom furosemid eller hydrochlorthiazid), der bruges mod forhøjet blodtryk o nogle typer medicin, der bruges til at behandle åndedrætsproblemer, kaldet metylxantiner (såsom teofyllin)
These include: o corticosteroids that you take by mouth (such as prednisolone), o diuretics (such as furosemide or hydrochlorothiazide) used for high blood pressure, o some medicines used to treat breathing conditions called methylxanthines (such as theophylline);
• du har en øjenlidelse, som kaldes snævervinklet glaukom (kaldes også lukketvinklet grøn stær)
• you have an eye problem called narrow-angle glaucoma (also called angle-closure glaucoma)
Samtidig behandling med methylxanthinderivater, steroider eller ikke-kaliumbesparende diuretika kan forstærke den mulige hypokaliæmiske virkning af β2-adrenerge agonister, hvorfor forsigtighed bør udvises ved samtidig brug (se pkt.
Concomitant treatment with methylxanthine derivatives, steroids, or non-potassium-sparing diuretics may potentiate the possible initial hypokalaemic effect of β2-adrenergic agonists, therefore, caution is advised in their concomitant use (see section 4.4).
Bevespi Aerosphere leveres som en trykbeholder med en dosisindikator, forsynet med et hvidt plasthylster og et mundstykke (se figur 1 i brugsvejledningen i slutningen af denne indlægsseddel).
Bevespi Aerosphere comes as a pressurised container with a dose indicator, supplied with a white plastic actuator body and mouthpiece (see Figure 1 of the Instructions for Use at the end of this leaflet).
Det Europæiske Lægemiddelagentur har dispenseret fra kravet om at fremlægge resultaterne af studier med Bevespi Aerosphere i alle undergrupper af den pædiatriske population med KOL (se pkt.
The European Medicines Agency has waived the obligation to submit the results of studies with Bevespi Aerosphere in all subsets of the paediatric population in COPD (see section 4.2 for information on paediatric use).
• Kun til inhalation
• For inhalation use only.
Dyrereproduktionsstudier af glycopyrronium har vist reduceret rotte- og kaninfostervægt og lav stigning i kropsvægt hos rotteafkom før afvænning blev observeret ved betydeligt højere systemisk eksponering end det, som blev opnået ved klinisk anvendelse.
Animal reproduction studies with glycopyrronium have shown reduced rat and rabbit fetal weights, and low body weight gain of rat offspring before weaning was observed at considerably higher systemic exposures than those reached during clinical use.
Bevespi Aerosphere bør administreres med forsigtighed til patienter, der behandles med lægemidler, som er kendt for at forlænge QTc-intervallet (se pkt.
Bevespi Aerosphere should be administered with caution to patients being treated with medicinal products known to prolong the QTc interval (see section 4.4).
• Fjern hætten fra mundstykket (se figur 3).
• Remove the cap from the mouthpiece (See Figure 3).
Trin 7: Når plasthylsteret er tørt, tryk forsigtigt trykbeholderen ned i plasthylsteret (se figur 18).
Figure 17 Step 7: When the actuator is dry, gently press the pressurised container down in the actuator (See Figure 18).
Behandlingsforskel (95 % konfidensintervaller, p-værdi) Trough-FEV1 (ml)
Treatment difference (95% confidence intervals, p-value)
Anvendes inden for 3 måneder efter åbning af posen.
2 years To be used within 3 months of opening the pouch.
Multipakning indeholdende 3 inhalatorer med 120 pust hver.
Multipack containing 3 inhalers each with 120 actuations.
Bevespi Aerosphere bruges til at lette vejrtrækningen hos voksne, der har en lungesygdom kaldet kronisk obstruktiv lungesygdom (KOL).
Bevespi Aerosphere is used to make breathing easier for adults who have a lung disease called chronic obstructive pulmonary disease (COPD).
Ved KOL strammes musklerne omkring luftvejene, hvilket gør vejrtrækningen vanskelig.
In COPD, the muscles around the airways tighten which makes breathing difficult.
Hypersensitivitetsreaktioner, herunder udslæt og kløe
Immune system disorders Hypersensitivity reactions including rash and pruritus
Figur 2b 110 doser
Figure 2b 110 puffs
I tre Fase-III, 24-ugers studier (PINNACLE 1, PINNACLE 2 og PINNACLE 4) viste Bevespi Aerosphere forbedringer i lungefunktionen over for placebo (målt ved lavest forceret respiratorisk volumen i 1 sekund [FEV1] om morgenen før dosering, med en påvist virkning på 5 minutter efter administration af den første dosis på dag 1 (forbedring over for placebo med 187 ml, 186 ml og 179 ml i henholdsvis PINNACLE 1, PINNACLE 2 og PINNACLE 4 [p<0,001]).
In three Phase III, 24-week studies (PINNACLE 1, PINNACLE 2 and PINNACLE 4) Bevespi Aerosphere provided improvements over placebo in lung function (as measured by morning pre-dose trough forced expiratory volume in 1 second [FEV1]), with a demonstrated onset of action at 5 minutes following administration of the first dose on Day 1 (improvement over placebo by 187 mL, 186 mL and 179 mL in PINNACLE 1, PINNACLE 2 and PINNACLE 4, respectively [p <0.001]).
Almindelig bivirkning relateret til formoterol bivirkning relateret til glycopyrronium
Common conditions adverse reaction relates to formoterol adverse reaction relates to glycopyrronium
Figur 2c 100 doser
Figure 2c 100 puffs
Tabel 2 Lungefunktion, symptomatiske og helbredsrelaterede livskvalitets-resultater ved uge 24
Table 2 Lung function, symptomatic and health related quality of life outcomes over 24 weeks Treatment comparisons with Bevespi
Brug ikke Bevespi Aerosphere, hvis du ammer, medmindre din læge har fortalt dig, at du kan bruge den.
Do not use Bevespi Aerosphere if you are breast-feeding unless your doctor tells you that you can.
Ved tryk på Bevespi Aerosphere udløses en mængde suspension fra trykbeholderen med stor hastighed.
On actuation of Bevespi Aerosphere, a volume of the suspension is expelled from the pressurised container at high velocity.
Hvis noget af ovenstående gælder for dig, eller hvis du er i tvivl, skal du tale med din læge eller apotekspersonalet, før du bruger Bevespi Aerosphere.
If any of the above applies to you, or if you are not sure, talk to your doctor or pharmacist before using Bevespi Aerosphere.
På grund af dets antikolinerge aktivitet bør Bevespi Aerosphere anvendes med forsigtighed til patienter med symptomatisk prostatahyperplasi, urinretention eller med snævervinklet glaukom (se pkt
Due to its anticholinergic activity, Bevespi Aerosphere should be used with caution in patients with symptomatic prostatic hyperplasia, urinary retention or with narrow-angle glaucoma (see section 4.8).
Bevespi Aerosphere indeholder to virksomme stoffer kaldet glycopyrronium og formoterolfumaratdihydrat.
Bevespi Aerosphere contains two active substances called glycopyrronium and formoterol fumarate dihydrate.
Trin 7: Ånd forsigtigt ud (se figur 12).
Step 7: Breathe out gently (See Figure 12).
Placebo korrigeret QT var 3,1 (4,7) ms for Bevespi Aerosphere (14,4 mikrogram/10 mikrogram) og 7,6 (9,2) ms for glycopyrronium/formoterol med otte gange den anbefalede dosis af glycopyrronium og fire gange den anbefalede dosis af formoterol.
The largest mean (90% upper confidence bound) differences from placebo in baseline- and individually corrected QT was 3.1 (4.7) ms for Bevespi Aerosphere (14.4 /10 micrograms) and 7.6 (9.2) ms for glycopyrronium/formoterol with eight times the recommended dose of glycopyrronium and four times the recommended dose of formoterol.
• Bevespi Aerosphere leveres som en trykbeholder med en dosisindikator, der passer ind i et plasthylster.
• Bevespi Aerosphere comes as a pressurised container with a dose indicator that fits into an actuator.
Antikolinerge aktiviteter
Anticholinergic activity
Overfølsomhed over for det aktive stof eller over for et eller flere af hjælpestofferne anført i pkt.
Hypersensitivity to the active substances or any of the excipients listed in section 6.1.
Almene symptomer og reaktioner på administrationsstedet
General disorders and administration site
Sådan bruger du Bevespi Aerosphere inhalator: Trin 1: Fjern hætten fra mundstykket (se figur 6).
Using your Bevespi Aerosphere inhaler: Step 1: Remove the cap from the mouthpiece (See Figure 6).
• Din Bevespi Aerosphere inhalator leveres i en foliepose, der indeholder en tørrepakke (tørremiddel).
• Your Bevespi Aerosphere inhaler comes in a foil pouch that contains a drying packet (desiccant).
Det betyder, at der er 110 doser tilbage i trykbeholderen (se figur 2b).
This means that there are 110 puffs of medicine left in the pressurised container (See Figure 2b).
Samtidig administration af Bevespi Aerosphere med andre lægemidler, der indeholder antikolinerge og/eller langtidsvirkende β2-adrenerge agonister, har ikke været undersøgt, og det anbefales ikke, da det kan forstærke bivirkningerne fra kendte muskarine antagonister til inhalation eller beta2-adrenerge agonister (se pkt.
Co-administration of Bevespi Aerosphere with other anticholinergic and/or long-acting β2-adrenergic agonist containing medicinal products has not been studied and is not recommended as it may potentiate known inhaled muscarinic antagonist or beta2-adrenergic agonist adverse reactions (see section 4.4 and section 4.9).
Karton indeholdende 1 inhalator med 120 pust.
Carton containing 1 inhaler with 120 actuations.
Dosisindikator
Dose indicator
1,2-distearoyl-sn-glycero-3-phosphocholin Calciumchlorid
1,2-distearoyl-sn-glycero-3-phosphocholine Calcium chloride
Bevespi Aerosphere kan anvendes i den anbefalede dosis til patienter med mild til moderat nyreinsufficiens.
Bevespi Aerosphere can be used at the recommended dose in patients with mild to moderate renal impairment.
Inhalationsspray, suspension (inhalationsspray).
Pressurised inhalation, suspension (pressurised inhalation).
Den terminale eliminationshalveringstid af formoterol efter oral inhalation var 13 timer, afledt via populationsfarmakokinetisk analyse.
The terminal elimination half-life of formoterol following oral inhalation derived via population pharmacokinetics analysis was 13 hours.
Den terminale eliminationshalveringstid af glycopyrronium efter oral inhalation var 15 timer, afledt via populationsfarmakokinetisk analyse.
The terminal elimination half-life of glycopyrronium following oral inhalation derived via population pharmacokinetics analysis was 15 hours.
Inhalatoren er en dosisinhalator under tryk, bestående af en aluminiumstrykbeholder med en vedhæftet dosisindikator, forsynet med et hvidt plasthylster og et mundstykke med en orange støvhætte.
The inhaler is a pressurised metered dose inhaler, comprising an aluminium pressurised container with an attached dose indicator, supplied with a white plastic actuator body and mouthpiece with an orange dust cap. Each inhaler is individually packaged in a foil laminate pouch containing a desiccant sachet and packed into a carton.
Fra populationen, der anvendte Ventoline anfaldsmedicin i PINNACLE 4 En hierarkisk statistisk testprocedure blev anvendt i dette studie, og sammenligningen var under en sammenligning, der ikke opnåede statistisk signifikans.
SAC-TDI was a primary endpoint in PINNACLE 1 and PINNACLE 2 only From the Rescue Ventolin User Population in PINNACLE 4 A hierarchical statistical testing procedure was used in this study and this comparison was below a comparison that did not achieve statistical significance.
Delene i Bevespi Aerosphere inhalator (se figur 1):
The parts of your Bevespi Aerosphere inhaler (See Figure 1):
Det betyder, at der er 100 doser tilbage i trykbeholderen (se figur 2c).
This means that there are 100 puffs of medicine left in the pressurised container (See Figure 2c).
Trin 1: Tag trykbeholderen ud af plasthylsteret (se figur 15).
Figure 14 Step 1: Take the pressurised container out of the actuator (See Figure 15).
Tag din dosis så snart du husker det, men hvis det næsten er tid til din næste dosis, skal du springe den glemte dosis over.
However, if it is nearly time for your next dose, skip the missed dose.
Dette svarer til en afmålt dosis glycopyrroniumbromid 10,4 mikrogram svarende til 8,3 mikrogram glycopyrronium og formoterolfumaratdihydrat 5,8 mikrogram.
This corresponds to a metered dose of glycopyrronium bromide 10.4 micrograms equivalent to 8.3 micrograms of glycopyrronium, and formoterol fumarate dihydrate 5.8 micrograms.
Trin 8: Sæt hætten på mundstykket straks efter brug (se figur 13).
Figure 12 Step 8: Replace the cap over the mouthpiece right away after use (See Figure 13).
Bevespi Aerosphere er en inhalationsspray, suspension.
Bevespi Aerosphere is a pressurised inhalation, suspension.
Bevespi Aerosphere viste også forbedringer i peak FEV1 inden for 2 timer efter dosis over 24 uger i forhold til placebo, glycopyrronium og formoterol (p<0,0001) [se tabel 2].
Bevespi Aerosphere also showed improvements in peak FEV1 within 2 hours post-dose over 24 weeks relative to placebo, glycopyrronium and formoterol (p<0.0001) [see Table 2].
Bevespi Aerosphere er indiceret som bronkodilaterende vedligeholdelsesbehandling til symptomlindring hos voksne patienter med kronisk obstruktiv lungesygdom (KOL) (se pkt.
Bevespi Aerosphere is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD) (see section 5.1).
o Brug ikke Bevespi Aerosphere trykbeholderen med et plasthylster fra nogen anden inhalator.
o Do not use the Bevespi Aerosphere pressurised container with an actuator from any other inhaler.
Til patienter med svær leverinsufficiens bør Bevespi Aerosphere kun anvendes, hvis den forventede fordel opvejer den potentielle risiko (se pkt.
In patients with severe hepatic impairment, Bevespi Aerosphere should be used only if the expected benefit outweighs the potential risk (see section 5.2).
Hos patienter med svær nyreinsufficiens eller med dialysekrævende terminal nyresygdom, bør det kun anvendes, hvis den forventede fordel opvejer den potentielle risiko (se pkt.
In patients with severe renal impairment or end-stage renal disease requiring dialysis it should be used only if the expected benefit outweighs the potential risk (see sections 4.4 and 5.2).
120 pust
120 actuations
• du har nyre- eller leverlidelser
• you have kidney or liver problems
Bevespi Aerosphere er beregnet til inhalation.
Bevespi Aerosphere is for inhalation use.
Hvis du har glemt at bruge Bevespi Aerosphere
If you forget to use Bevespi Aerosphere
Hvis du holder op med at bruge Bevespi Aerosphere
If you stop using Bevespi Aerosphere
Det skal du vide, før du begynder at bruge Bevespi Aerosphere
What you need to know before you use Bevespi Aerosphere
Mundtørhed 2, kvalme
Gastrointestinal disorders Dry mouth 2, Nausea
o Brug ikke Bevespi Aerosphere plasthylsteret med nogen anden medicin.
o Do not use the Bevespi Aerosphere actuator with any other medicine.
Hvis du er i tvivl, skal du tale med lægen eller apotekspersonalet, før du bruger Bevespi Aerosphere.
If you are not sure, talk to your doctor or pharmacist before using Bevespi Aerosphere.
INHALATORETIKET (TRYKBEHOLDER)
INHALER LABEL (PRESSURISED CONTAINER)
o Tag Bevespi Aerosphere inhalatoren ud af folieposen.
o Take the Bevespi Aerosphere inhaler out of the foil pouch.
Norfluran, 1,2-distearoyl-sn-glycero-3-phosphocholin og calciumchlorid.
Norflurane 1,2-distearoyl-sn-glycero-3-phosphocholine and calcium chloride.
I studierne PINNACLE 1, PINNACLE 2 og PINNACLE 4 viste Bevespi Aerosphere forbedringer i trough-FEV1 over 24 uger i forhold til placebo, glycopyrronium og formoterol (p<0,0001) [se tabel 2].
In studies PINNACLE 1, PINNACLE 2 and PINNACLE 4, Bevespi Aerosphere showed improvements in trough FEV1 over 24 weeks relative to placebo, glycopyrronium and formoterol (p<0.0001) [see Table 2].
Farmakokinetikken for formoterol blev bedst beskrevet ved en to-kammerdispositionsmodel med en 1. ordens konstant absorptionsrate og lineær elimination.
The pharmacokinetics of formoterol was best described by a two compartment disposition model with a first-order rate constant of absorption and linear elimination.The typical clearance (CL/F) of formoterol was 99 L/h.
NAVN PÅ INDEHAVEREN AF MARKEDSFØRINGSTILLADELSEN
NAMES OF THE MARKETING AUTHORISATION HOLDER
Imidlertid bør det ved kørsel eller ved brug af maskiner tages i betragtning, at svimmelhed og kvalme er almindelige bivirkninger.
However dizziness and nausea are common side effects which should be taken into account when driving or using machines.
Bevespi Aerosphere bør kun anvendes i ammeperioden, hvis fordelene for moderen opvejer de eventuelle risici for barnet (se pkt.
Administration of Bevespi Aerosphere to women who are breast-feeding should only be considered if the expected benefit to the mother is greater than any possible risk to the infant (see section 5.3).
Brug af Bevespi Aerosphere med en spacerenhed Hvis du har svært ved at trække vejret ind og trykke på inhalatoren samtidig, kan du tale med din læge eller apotekspersonalet, da du muligvis kan bruge en spacerenhed med din inhalator.
If you find it difficult breathing in and pressing the inhaler at the same time talk to your doctor or pharmacist.
- Øvrige indholdsstoffer: norfluran, 1,2-distearoyl-sn-glycero-3-phosphocholin og calciumchlorid.
The other ingredients are norflurane, 1,2- distearoyl-sn-glycero-3-phosphocholine and calcium chloride.
Figur 13
Figure 13